, /PRNewswire/ -- The global nicotine gum market size is estimated to grow by from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.71% during the forecast period.
Increasing number of people trying to quit smoking is driving market growth, with a trend towards growing new product launches related to nicotine. However, health issues associated with smoking cessation products poses a challenge. Key market players include Alchem International Pvt.
Ltd., Alkalon AS, British American Tobacco Plc, Cambrex Corp., Cipla Inc.
, Dr Reddys Laboratories Ltd., Enorama Pharma AB, Fertin Pharma AS, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ITC Ltd.
, Johnson and Johnson Services Inc., Leeford Healthcare Ltd., Lil Drug Store Products Inc.
, Lucy Goods Inc., Major Pharmaceuticals Inc., Perrigo Co.
Plc, Rogue Holdings LLC, Trumac Healthcare, and Walgreens Boots Alliance Inc.. Get a detailed analysis on regions, market segments, customer landscape, and companies- New product launches, such as Perrigo Company plc's nicotine-coated mint lozenges, contribute significantly to revenue growth and market expansion in the nicotine gum market.
These lozenges, approved by the US FDA in , are anticipated to generate sales comparable to national brand products, which reached approximately in the previous year. By addressing the needs of consumers attempting to quit smoking, these product launches will positively impact the global nicotine gum market during the forec.
